MENU
RARE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Ultragenyx Pharmaceutical (RARE) Earnings Date & Reports

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

RARE is expected to report earnings to fall 79.54% to -23 cents per share on February 18

Ultragenyx Pharmaceutical RARE Stock Earnings Reports
Q4'26
Est.
$-0.24
Q3'26
Missed
by $0.01
Q2'26
Beat
by $0.32
Q1'26
Missed
by $0.38
Q4'25
Missed
by $0.14
The last earnings report on November 03 showed earnings per share of -115 cents, missing the estimate of -114 cents. With 2.90M shares outstanding, the current market capitalization sits at 1.52B.
A.I.Advisor
Nov 03, 2026

Ultragenyx Pharmaceutical (RARE) Q3 2026 Earnings Recap: Gene Therapy Momentum Meets Cost Discipline

Key Takeaways

  • Ultragenyx reported third-quarter 2026 total revenue of $173 million, up from $160 million a year earlier but below the roughly $182 million consensus estimate.
  • Net loss narrowed to $118 million, or $1.16 per share, from $180 million, or $1.81 per share, in the prior-year quarter, still a wider loss than analysts expected.
  • Crysvita revenue slipped to $109 million from $112 million, while Dojolvi ($30 million), Evkeeza ($24 million), and Mepsevii ($10 million) all grew year over year.
  • Management reaffirmed 2026 revenue guidance of $730 million to $760 million and reiterated its goal of full-year GAAP profitability in 2027.
  • The company announced a roughly 20% workforce reduction and lower planned 2027 operating expenses, alongside two new gene therapy approvals during the quarter.
  • For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
  • Discover actionable market ideas with Trending AI Robots.

Earnings Context and Why It Matters

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on rare and ultra-rare genetic diseases, a segment where a small patient base must support high-value, often curative therapies. This quarterly report matters because it tests whether the company's expanding commercial franchise can offset rising pipeline investment while it still posts losses. In the prior quarter, Ultragenyx delivered record revenue of $214 million, so the sequential decline into the third quarter raised questions about commercial momentum. Investors are also watching two newly approved gene therapies and a $413 million sale of priority review vouchers (PRVs) as signals of whether management can reach its 2027 profitability target.

Reported Results

For the third quarter of 2026, Ultragenyx reported total revenue of $173 million, an increase from $160 million in the year-ago period but below the consensus estimate of approximately $182 million. Net loss narrowed to $118 million, or $1.16 per share, compared with a net loss of $180 million, or $1.81 per share, a year earlier. Analysts had projected a smaller loss of about $1.10 per share, so the bottom line also fell short of expectations.

Revenue by product showed mixed results. Crysvita revenue declined to $109 million from $112 million. Dojolvi revenue rose to $30 million from $24 million, Evkeeza revenue increased to $24 million from $17 million, and Mepsevii revenue grew to $10 million from $7 million. Total operating expenses decreased to $283 million from $331 million, with research and development (R&D) expense falling to $154 million from $216 million, reflecting the company's cost-reduction initiatives.

Ultragenyx reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million, excluding potential revenue from new product launches, and reiterated its expectation of full-year GAAP (Generally Accepted Accounting Principles) profitability in 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like Ultragenyx, it offers a structured way to spot emerging setups and monitor shifting market conditions. Explore the AI Screener to streamline your research.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report was cautious, with the stock already down sharply from its 52-week high. Shares closed at $16.69 ahead of the announcement, reflecting declines of roughly 36% over the prior three months and nearly 49% over the past year. After the results missed both revenue and earnings expectations, the stock fell about 6% in after-hours trading. The muted reaction reflects a tension between near-term execution and longer-term catalysts: investors are weighing the modest sequential revenue dip and lower Crysvita contribution against two landmark gene therapy approvals and a substantial capital infusion from PRV sales.

Forward Outlook and Key Factors to Monitor

Looking ahead, Ultragenyx is entering a pivotal period shaped by both cost discipline and new product launches. The company announced a workforce reduction of approximately 20% and plans to cut 2027 R&D expenses below $350 million and selling, general, and administrative (SG&A) expenses below $375 million, moves designed to narrow losses and support the 2027 profitability target.

On the commercial side, investors will watch the launch of Genglycos, approved for glycogen storage disease type Ia, and Fayuvi, the first treatment for Sanfilippo syndrome type A (MPS IIIA). Both were approved by the U.S. Food and Drug Administration (FDA) during the third quarter and represent the company's first gene therapy launches. Their uptake will be a key driver of whether Ultragenyx can exceed its 2026 guidance, which currently excludes new-launch revenue.

Other factors to monitor include Crysvita ordering patterns, particularly in Latin America and Turkey, continued Evkeeza expansion outside the United States, and any readouts from late-stage pipeline programs. The company's balance sheet remains a point of focus as well, with management reaffirming its path to profitability while balancing R&D investment against disciplined expense control.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics for rare diseases

Industry Biotechnology

Industry
Biotechnology
Address
60 Leveroni Court
Phone
+1 415 483-8800
Employees
1371
Web
https://www.ultragenyx.com